Publicaciones (184) Publicaciones de Carlos de las Cuevas Castresana

2024

  1. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)

    Schizophrenia Research, Vol. 268, pp. 165-174

  2. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 53-59

  3. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 60-65

  4. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature

    Expert Opinion on Drug Safety

  5. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database

    Schizophrenia Research, Vol. 268, pp. 118-130

  6. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies

    Schizophrenia Research, Vol. 268, pp. 293-301

  7. Exploring the Relationship Between Psychological Constructs and Decision-Making Preferences in Psychiatric Outpatients

    Patient Preference and Adherence , Vol. 18, pp. 1629-1640

  8. Implications of psychological reactance for clinical practice in psychiatry including a systematic review.

    Motivation Science

  9. Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 20, Núm. 8, pp. 857-871

  10. Psychoeducational group interventions for adults diagnosed with attention-deficit/ hyperactivity disorder: a scoping review of feasibility, acceptability, and outcome measures

    BMC Psychiatry, Vol. 24, Núm. 1

  11. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK

    Schizophrenia Research, Vol. 268, pp. 175-188

2023

  1. Escaping the Long Shadow Cast by Agranulocytosis: Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom

    Journal of Clinical Psychopharmacology, Vol. 43, Núm. 3, pp. 239-245

  2. Evaluating the Effect of a Telepsychiatry Educational Program on the Awareness, Knowledge, Attitude, and Skills of Telepsychiatry Among Spanish Psychiatrists during COVID-19 Pandemic

    Telemedicine and e-Health, Vol. 29, Núm. 1, pp. 102--108

  3. Guía internacional para una dosificación más segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la proteína C reactiva y los niveles de clozapina

    Psiquiatría Biológica, Vol. 30, Núm. 3, pp. 100415

  4. Guía internacional para una dosificación más segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la proteína C reactiva y los niveles de clozapina

    Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica, Vol. 30, Núm. 3

  5. NURSING STUDENT’S VIEWS ON THE DUTY OF CARE: A CROSS-SECTIONAL STUDY IN TWO COUNTRIES

    International Journal of Person Centered Medicine, Vol. 11, Núm. 2, pp. 35-50

  6. Psychiatric Patients’ Perceived Health Control and Reactance: Implications for Medication Adherence

    Patient Preference and Adherence, Vol. 17, pp. 1591-1601

  7. Reflexionando sobre las técnicas neurocientíficas: tecnofilia y tecnofobia

    Técnicas neurocientíficas aplicadas a la salud (Ediciones Piramide), pp. 317-327

  8. Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 19, Núm. 2, pp. 57-74

  9. Will ChatGPT3 Substitute for us as Clozapine Experts?

    Journal of clinical psychopharmacology, Vol. 43, Núm. 5, pp. 400-402